About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, January 30th, 2018

The QualityStocks
Daily Stock List


Propanc Biopharma, Inc. (PPCB)

Investing News and InvestorsHub reported on Propanc Biopharma, Inc. (PPCB), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Propanc Biopharma, Inc. is a clinical stage biopharmaceutical company listed on the OTCQB. It focuses on the development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian, and colorectal cancers. The Company has developed a formulation of anti-cancer compounds that exert many effects designed to control or prevent tumors from recurring and spreading throughout the body. Propanc Biopharma is based in Australia.

The Company is developing a long-term therapy based on a pancreatic proenzyme formulation to prevent tumour recurrence and metastasis. Its lead product, PRP, is a novel, patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is a solution for once daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen, for the treatment of pancreatic cancer.

Propanc Biopharma (after extensive laboratory research and a limited amount of human testing) has evidence that PRP decrease cancer cell growth via promotion of cell differentiation; enhances cell adhesion and may suppress metastasis progression; and has no serious side effects and improves patient survival.

The Company has received Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for the use of its lead product, PRP. The approved indication is one of the most lethal malignancies with a median survival of 6 months and a 5-year survival rate of under 5 percent.

Recent development progress for PRP includes successful completion of a GLP-compliant, 28-day repeat-dose toxicity study with no toxicological findings after administration. This indicates a broad safety margin. It provides adequate data to support a safe starting dose for First-In-Human studies.

Recently, Propanc Biopharma announced it submitted a request for Orphan Drug Designation (ODD) to the FDA for PRP, a solution for once daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen. The proposed orphan drug indication for PRP is the treatment of ovarian cancer.

Mr. James Nathanielsz, Chief Executive Officer of Propanc Biopharma, said, "Obtaining orphan drug designation from the FDA for our PRP therapy for ovarian cancer is a significant regulatory milestone that we are looking forward to, and will be a positive step forward in Propanc Biopharma's ongoing efforts to develop effective treatments for metastatic cancer."

Last week, Propanc Biopharma announced that it has made considerable recent progress towards full scale Good Manufacturing Process (GMP) manufacture of its lead product, PRP, for First-In-Human studies, expected to begin next year.

Research and development activities conducted with the Company’s European Contract Manufacturing Organization (CMO) experienced in the production of biopharmaceuticals, have been successful in developing a process that can purify and stabilize the two active drug substances of the PRP formulation, trypsinogen and chymotrypsinogen.

This is a vital requirement during the manufacturing process. Therefore, Propanc is ready to start engineering runs of manufacturing the finished drug product, before full scale GMP manufacture of PRP for human trials.

Propanc Biopharma, Inc. (PPCB), closed Tuesday's trading session at $0.145, up 3.57%, on 392,021 volume with 58 trades. The average volume for the last 60 days is 546,493 and the stock's 52-week low/high is $0.09/$3.35.

TapImmune, Inc. (TPIV)

Penny Stocks Finder, InvestorSoup, Penny Pick Finders, Stock News Now, SeeThruEquityResearch, Stock Preacher, Beacon Equity Research, SuperStockTips, Penny Stock Craze, and Pennybuster reported earlier on TapImmune, Inc. (TPIV), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

TapImmune, Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical studies presently continuing for the treatment of ovarian and breast cancer. The Company’s peptide or nucleic acid-based immunotherapeutics consist of one or multiple naturally processed epitopes (NPEs). The design of these is to comprehensively stimulate a patients' killer T-cells, helper T-cells, and to restore or further augment antigen presentation through using proprietary nucleic acid-based expression systems. TapImmune is based in Jacksonville, Florida.

The Company has developed an innovative, cost effective, immunotherapeutic vaccine expression and delivery system. The novel platform is called TapImmune's PolyStart™ technology. The PolyStart and PAA (Peptide Antigen Array) technologies are straight forwardly and easily managed as a fast, adaptable, plugin-and-play system. This means they can be configured to produce peptides for any desired pathogen.

TapImmune’s PolyStart™ technology has been strategically designed to directly enhance the immune system's ability to stimulate either or both cytotoxic killer and helper T-cell reactive proprietary peptides, known and expected to be associated with one, or any cancer, infectious disease, or bio-threat. The current emphasis of its PolyStart technology is on its cancer program (e.g., Her2/neu and folate receptor alpha antigens).

This past November, TapImmune announced that it has enrolled the final patient in a randomized Phase 2 clinical study of its novel T-cell vaccine candidate TPIV200 for treating triple-negative breast cancer (TNBC). The design of the wide-ranging four-arm study is to help determine the optimal vaccine dose and regimen to maximize the immune response generated against the vaccine's molecular target, folate receptor-alpha (FRa). This is a cancer cell biomarker that is highly correlated with disease recurrence.

Moreover, TapImmune started enrolling patients into a Phase 2 platinum-sensitive ovarian cancer study under an amended protocol that allows women in their first remission to receive TPIV200 vaccination. In addition, the Company continued to advance its clinical development pipeline in manifold Phase 2 studies in ovarian and breast cancer.

Last month, TapImmune announced that the first patient was enrolled in a Phase 2 randomized, multi-center, double-blinded, placebo-controlled clinical trial of TapImmune's novel therapeutic vaccine candidate TPIV200. The 280-patient trial, sponsored by Mayo Clinic, received $13.3 million in grant funding from the U.S. Department of Defense (DoD) to evaluate the prevention of cancer recurrence in women with triple-negative breast cancer (TNBC) who have completed first-line surgery and radiotherapy/chemotherapy.

TapImmune, Inc. (TPIV), closed Tuesday's trading session at $3.71, down 0.80%, on 26,082 volume with 60 trades. The average volume for the last 60 days is 44,713 and the stock's 52-week low/high is $2.601/$5.35.

Bion Environmental Technologies, Inc. (BNET)

Wall Street Resources, OTC Stock Review, TopPennyStockMovers, SECFilings News, and Stock Guru reported earlier on Bion Environmental Technologies, Inc. (BNET), and today we report on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed Bion Environmental Technologies, Inc. is a developer of advanced livestock waste treatment and resource recovery technology. Its patented, next-generation technology provides verified comprehensive treatment of animal waste from large-scale livestock production facilities. Bion Environmental Technologies has its corporate office in Crestone, Colorado, and its administrative office in Old Bethpage, New York.

Bion’s technology platform achieves substantial reductions in environmental impacts. This includes nutrients (nitrogen and phosphorus), ammonia, greenhouse and other gases, and pathogens in the waste stream. This is while improving resource and operational efficiencies through the recovery of valuable byproducts.

The Company’s technology platform is a modular system. It can be configured in a variety of ways, depending on farm- and region-specific requirements. The system creates new revenue sources and opportunities for the producer.

Bion’s 2nd generation (2G) Comprehensive Environmental Management System removes up to 95 percent of the nutrients from the livestock waste effluent. It significantly lessens air emissions. This includes ammonia (as great as 90 percent or more), greenhouse gases, hydrogen sulfide, VOC’s, and others. The system extracts renewable energy from the waste stream in the form of cellulosic biomass.

The Company announced in July 2017 that it filed a continuation of its September 2015 patent for a livestock ammonia recovery process. This process converts the ammonia into stable ammonium bicarbonate.

Bion’s anticipation is that the ammonium bicarbonate produced in its system can be certified for use in organic production. Organic certification for its ammonium bicarbonate will result in significantly higher values than chemically-produced alternatives. The Company’s anticipation is that the leftover residual solids that contain the remaining nitrogen, as well as salts and minerals, can also undergo processing to qualify for organic use as a soil amendment product, depending on market values.

Bion’s treatment solutions are a combination of biological, mechanical, and thermal processes. These are proven in commercial operations. They have been accepted by the EPA (Environmental Protection Agency), the USDA (United States Department of Agriculture), and other regulatory agencies.

This past October, Bion Environmental Technologies announced that the Pennsylvania Clean Water Procurement Act (SB 799) was successfully voted out of the Pennsylvania Senate Environmental Resources and Energy Committee by a 10-2 vote. It will next be scheduled for consideration in the Senate.

SB 799 is a government reform bill. It will allow the private sector to provide low-cost solutions to Pennsylvania’s Chesapeake Bay obligations, and also the Commonwealth’s own drinking water issues.

Mr. Craig Scott, Bion Environmental Technologies’ Communications Director, said, “We are very encouraged that the Committee has now advanced SB 799 for consideration in the Senate. While there is still work to be done in both the Senate and House, we remain confident that the bill offers the best-case scenario for Pennsylvania’s Bay mandates, as well as the state’s own water quality issues and its taxpayers. Pennsylvania needs to use all the tools available to meet the environmental challenges it faces – and that includes the private sector.”

Bion Environmental Technologies, Inc. (BNET), closed Tuesday's trading session at $0.76, up 8.57%, on 6,701 volume with 9 trades. The average volume for the last 60 days is 6,465 and the stock's 52-week low/high is $0.44/$1.02.

Biostage, Inc. (BSTG)

StockTwits, Zacks, Investors Hub, Stock News Gazette, StockNewsJournal, Simply Wall St, BusinessInsider, Barchart, The Street, InvestorPoint, and AllStockNews reported on Biostage, Inc. (BSTG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Established in 2007, Biostage, Inc. is a biotechnology company listed on the OTC Markets Group’s OTCQB. It is developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea. The Company previously went by the name Harvard Apparatus Regenerative Technology, Inc. It changed its name to Biostage, Inc. in March of 2016. Biostage has its corporate office in Holliston, Massachusetts.

The Company is developing bioengineered organ implants founded on its Cellframe™ technology. This technology combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants.

Cellspan implants are undergoing development to treat life-threatening conditions of the esophagus, bronchus or trachea with the hope of significantly improving the treatment paradigm for patients. Biostage, based on its preclinical data, has chosen life-threatening conditions of the esophagus as the first clinical application of its technology.

The Cellspan implant is delivered directly to the site where tissue regeneration is required. It is intended to play a pivotal role in the success of in situ tissue regeneration through providing stem cell-derived biological signals, and three-dimensional guidance and support, for cell growth and regeneration.

Biostage’s novel Cellframe™ technology is engineered to stimulate the body’s signaling pathways and natural healing process to regenerate and restore organ function. Its Cellframe technology is based on more than two decades of scientific progress in the fields of tissue engineering, cell biology, and material science. Cellframe technology combines the best attributes of a synthetic scaffold with tissue engineering and cell biology.

In August of 2017, Biostage announced the use of its Cellspan Esophageal Implant product candidate in a patient at a major U.S. hospital through a Food and Drug Administration (FDA)-approved single-use expanded access application. Within a collaborative agreement between Biostage and The University of Texas Health Science Center at Houston (UTHealth), the patient's own stem cells were processed, seeded, and grown onto the scaffold at the Cellular Therapy Core of the Program in Children's Regenerative Medicine at UTHealth, before release for transport to the institution carrying out the surgery.

Earlier this month, Biostage announced the funding and closing of a private placement with a group of investors from China for total gross proceeds of roughly $4.1 million. Moreover, Connecticut Children's Medical Center also participated in the transaction by purchasing additional securities. Biostage’s plan is to establish a presence in China to address the largest incidence of esophageal cancer globally.

Biostage has built a dedicated internal team of materials scientists, engineers and biologists. They are working with the Company’s external collaborators to bring Biostage products to the patients who need them as fast as possible.

Biostage, Inc. (BSTG), closed Tuesday's trading session at $3.24, even for the day, on 1,831 volume with 18 trades. The average volume for the last 60 days is 1,679 and the stock's 52-week low/high is $0.60/$16.616.

Acura Pharmaceuticals, Inc. (ACUR)

PennyOmega, PennyToBuck, StreetInsider, Marketbeat, SmarTrend Newsletters, Wall Street Resources, PennyStocks24, Penny Stock Rumble, The Street, BestOtc, BUYINS.NET, CRWEFinance, CRWEWallStreet, StockHotTips, and DrStockPick reported earlier on Acura Pharmaceuticals, Inc. (ACUR), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company innovating abuse deterrent drugs. It engages in the research, development, and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary LIMITx™, IMPEDE®, and AVERSION®, Technologies. Acura Pharmaceuticals is headquartered in Palatine, Illinois.

The intention of the Company’s LIMITX™ Technology is to address an oral Excessive Tablet Abuse (ETA) or accidental consumption of multiple tablets, as well as provide a margin of safety during accidental over-ingestion of tablets. Additionally, LIMITX™ is expected to exhibit barriers to abuse by snorting and injection. LTX-04 is Acura’s lead development candidate using its novel LIMITx™ technology.

The IMPEDE® Technology platform is an advanced polymer matrix. It is used in NEXAFED®, Acura Pharmaceuticals’ pseudoephedrine (PSE) tablet product, to limit or disrupt the extraction of PSE from tablets for conversion into the illicit drug methamphetamine.

AVERSION® Technology is a patented composition of commonly used active and inactive pharmaceutical ingredients providing abuse deterrent features and benefits for orally administered pharmaceutical drug products. The intention of AVERSION® Technology opioid analgesic product candidates is to provide effective relief from pain. This is while discouraging common methods of pharmaceutical product misuse and abuse.

OXAYDO® (oxycodone HCl immediate-release tablets) that incorporate the AVERSION Technology, is Food and Drug Administration (FDA) approved and marketed in the United States by Acura Pharmaceuticals’ partner Egalet Corp. NEXAFED® and NEXAFED® Sinus are pseudoephedrine containing products that use the IMPEDE Technology. They are marketed in the U.S. by Acura’s partner MainPointe Pharmaceuticals.

This month, Acura Pharmaceuticals announced that topline results from clinical study AP-LTX-301 (Study 301) for its LIMITx™ excess oral abuse deterrent drug LTX-03 identified a formulation, which the Company believes optimizes the balance between providing therapeutic blood levels of drug for pain relief at a single tablet dose while holding back the bioavailability of drug when higher buffer levels are ingested.

Acura Pharmaceuticals’ intention is to submit an Investigational New Drug application (IND) for LTX-03 to the FDA in Q1 2018 and advance to clinical development for a New Drug Application (NDA). Present FDA approved abuse deterrent opioid formulations do not address abuse by swallowing excess numbers of tablets.

Dr. Al Brzeczko, Acura Pharmaceuticals’ Vice President of Technical Affairs, said, “With Study 301 we believe we have identified a per tablet buffer level that demonstrated good pharmacokinetics for both the efficacious and abused dose levels. We are excited to advance LTX-03 to the IND phase and look forward to beginning the NDA development process.”

Acura Pharmaceuticals, Inc. (ACUR), closed Tuesday's trading session at $0.60, down 14.59%, on 25,195 volume with 29 trades. The average volume for the last 60 days is 28,740 and the stock's 52-week low/high is $0.2855/$1.40.

Northern Superior Resources, Inc. (NSUPF)

24h Gold, MarketWatch, Stockhouse, YCharts, OTC Markets, TraderPlanet, 4-Traders, Stock Press Daily, Stockwatch, Barchart, PennyStockHub, Investing News Alerts, thehotpennystocks, and Jet Life Penny Stocks reported on Northern Superior Resources, Inc. (NSUPF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Northern Superior Resources, Inc. engages in the identification, acquisition, evaluation, and exploration of gold properties in the Provinces of Ontario and Quebec. An exploration stage junior mining company, it was founded as a diamond exploration Company in 2002, under the name Superior Diamonds, Inc. In 2007, the Company transformed into a gold exploration enterprise and renamed itself Northern Superior Resources, Inc. OTCQB-listed, Northern Superior Resources is based in Sudbury, Ontario.

The Company is presently focused on exploring its 100 percent owned Croteau Est (Quebec) and Ti-pa-haa-kaa-ning (Northwestern Ontario) properties. Its remaining properties (all 100 percent owned) in Quebec and Northwestern Ontario are available for option.

Northern Superior Resources identifies exploration opportunities from its immense geoscientific data base and advances them through to discovery. Its intention is to ultimately option, joint venture (JV) or sell the asset.

The Croteau Est property is in one of Quebec’s more important and historic mining camps, Chapais- Chibougamau. The property measures roughly 30km east to west by 10-15km north to south. An inferred gold resource is defined on this property by Northern Superior: 640,000 ounces of gold (with a cut off of 1.0 g/ t Au, totaling 11.6 million tonnes grading 1.7ppm gold).

Furthermore, an additional exploration target, ranging from 3.2 to 3.8 million tonnes, for a total of 122,000 to 270,000 ounces of gold, was identified from mineralization, defined by single drill-hole intersections in the same deposit.

The Ti-pa-haa-kaa-ning (TPK- gold/silver/copper) property in northwestern Ontario is 30 x 20km. It contains two regional, strong and independent mineral systems. One is a gold-bearing shear system at least 24km long. The second is a newly discovered greenstone belt assaying as high as 727 g/t gold, 111 g/t silver and 4.05 percent copper.

Recently, Northern Superior Resources reported the results of its August 2017 till sampling program on the Annex portion of its Ti-pa-haa-kaa-ning (TPK) property. This portion of the property encloses one of two, district scale mineralized systems. These are recognized for their gold, silver, and copper potential.

Dr. T.F. Morris, Northern Superior Resources’ President and Chief Executive Officer, stated, "Similar to the work program recently completed in the Big Dam area (see Northern Superior press release, November 8, 2017), re-evaluation and integration of several layers of geoscientific data for the Annex area has identified 22 highly prospective targets where the potential for gold, silver and copper mineralization is seen to exist. The work to date indicates the potential for multiple targets in the Annex area and an exceptional opportunity to unlock the gold, silver and copper potential of the Annex area of the TPK property."

Earlier this month, Northern Superior Resources reported results from the recently completed Phase III drill program (November- December 2017) within the Croteau Bouchard Shear Zone (CBSZ) on its 100 percent owned Croteau Est Gold Property, Quebec. Sixteen core drill holes totaling 6,282 meters (m) of drilling were completed for this phase.

At present, the Company is updating its three-dimensional geological model for the CBSZ. This will further illustrate the structural continuity of mineralization associated with the several high-grade, gold-bearing shoots embedded within the CBSZ. In addition, it will help in understanding the potential of the CBSZ as a gold deposit.

Northern Superior Resources, Inc. (NSUPF), closed Tuesday's trading session at $0.0341, down 2.57%, on 62,000 volume with 3 trades. The average volume for the last 60 days is 27,660 and the stock's 52-week low/high is $0.02/$4.63.

Blue Sphere Corp. (BLSP)

Fast Money Alerts, Stock Shock and Awe, PremiereStockAlerts, DreamTeamNetwork, MyBestStockAlerts, OTPicks, Penny Stock General, PennyStocks24, and SmallCapVoice reported earlier on Blue Sphere Corp. (BLSP), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Blue Sphere Corp. is a global Independent Power Producer (IPP). The Company is working to become a key player in the international waste-to-energy and renewable energy markets. It has a business plan that fits the changing regulatory standards for waste and energy.

A clean-technology waste-to-energy producer, Blue Sphere’s primary business model is BOO (Build-Own-Operate) - long-term energy agreements are executed with electric companies in advance of projects. Blue Sphere has its headquarters in Charlotte, North Carolina. A waste-to-energy project integrator, the Company has operations in the United States, Israel, and Europe. Blue Sphere lists on the OTC Markets’ OTCQB.

Blue Sphere is performing waste-to-energy projects in the United States and Italy. It is pursuing a strategy to work in association with landfill owners to convert harmful methane gas emissions from landfills into electricity. The process is established on readily available technology already being used in different parts of the United States and other areas globally.

Blue Sphere has its Charlotte, North Carolina Waste to Energy Anaerobic Digester 5.2 MW Plant. In Johnston, Rhode Island, the Company has its Waste to Energy Anaerobic Digester 3.2 MW Plant.

Blue Sphere, by way of its wholly-owned subsidiaries, completed the acquisition of four operating biogas the Company’s history. Blue Sphere acquired 100 percent of the stock of Agricerere, S.R.L., Agrielektra, S.r.L., Agrisorse, S.r.L. and Gefa, S.r.L.

Individually, each fully operational facility produces one megawatt of electricity per hour, which sells to Gestore del Servizi Energetici GSE, S.p.A., a state owned company that promotes and supports renewable energy sources in Italy, under a Power Purchase Agreement (PPA) that runs through December 31, 2027.

Last month, Blue Sphere provided an update on activities for its projects in Udine, Italy and Sterksel, Netherlands. In Udine, Italy, Blue Sphere has realized its goal and the facility is operating at 95 percent of capacity as of November 5, 2017.

For Sterksel, Netherlands, the Company has met important milestones in the development of its landmark project in Holland. On December 4, 2017, Blue Sphere entered into a definitive EPC agreement with Anergia B.V. The agreement includes a turnkey agreement for the design, construction and delivery of a Biogas Plant, a service, maintenance and operation Agreement and a performance guarantee.

Blue Sphere Corp. (BLSP), closed Tuesday's trading session at $2.00, up 17.65%, on 610 volume with 6 trades. The average volume for the last 60 days is 1,934 and the stock's 52-week low/high is $1.20/$10.00.

MariMed, Inc. (MRMD)

Investors Hub, OTC Markets, and DailyMarijuanaObserver reported on MariMed, Inc. (MRMD), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

MariMed, Inc. is an industry leader in the design, development, operation, funding, and optimization of medical cannabis cultivation and production centers and dispensaries. The Company provides turnkey solutions to cannabis cultivators, producers, and dispensaries. It specializes in solutions for securing and operating facilities, manufacturing and processing, dispensary, layouts, and designs, merchandising and sales. OTCQB-listed, MariMed has its corporate office in Newton, Massachusetts.

MariMed is focusing exclusively on serving the fast expanding $7 billion legal cannabis industry. MariMed reported strong revenue growth for 2016 that continued into 2017. The Company more than doubled revenue in 2016 over 2015, increasing from $1.27 million in 2015 to $3.56 million in 2016. Most of the revenue was attributable to subsidiary MariMed Advisors and its cannabis services and products business.

MariMed is on the vanguard of medical research, working to create precision dosed products to treat specific conditions. Its team has developed state-of-the-art and regulatory compliant facilities in numerous states. These facilities are replicable and scalable models of excellence in horticultural principals, cannabis production, product development, as well as dispensary operations.

The Company provides a complete range of consulting services in the medical cannabis industry. It uses a systematic approach, from the permit and application process, to on-time operational readiness. As Cannabis experts, it specializes in supporting the development of high quality state-licensed, medical cannabis dispensaries and cultivation facilities.

MariMed’s services include application assistance, real estate and safe access, build-out and ongoing consultation, business acceleration solutions, and physician and patient outreach. MariMed Advisors, Inc. has a portfolio of high-quality branded products, product development plans, product packaging, and product licensing opportunities.

In November, MariMed announced that it acquired the rights to the intellectual property (IP), formulations, recipes, proprietary equipment, and expertise of Betty’s Eddies from Icky Enterprises LLC. This acquisition enables MariMed to further expand its inventive, industry-leading Kalm Fusion™ precision dosed medical cannabis-infused product line.

Betty’s Eddies is a line of fruit chews handcrafted and naturally sweetened with the finest all natural ingredients and non-GMO organic fruits and vegetables. MariMed has a licensing agreement where Canuvo, Inc., will manufacture and distribute MariMed Kalm Fusion™ and Betty’s Eddies™ branded medical cannabis products in Maine.

Recently, MariMed announced the purchase of a 137,500 sq. ft. industrial building on 17 acres at 167 John Vertente Blvd., in the New Bedford, Massachusetts industrial park for a purchase price of $6,895,000. MariMed will develop roughly 70,000 sq. ft. into a full service state of the art medical cannabis cultivation and production facility. This has been leased to ARL Healthcare, Inc. (ARL), a Massachusetts not for profit corporation.

MariMed assisted ARL Healthcare in its successful application to be awarded a Massachusetts Registered Marijuana Dispensary (RMD) License for cultivation, production, and dispensing of medical cannabis. MariMed will assist ARL Healthcare in the development and ongoing management of the cultivation and manufacturing facility. ARL expects to start cultivation in Q1 of 2018.

MariMed, Inc. (MRMD), closed Tuesday's trading session at $1.1624, up 5.67%, on 595,579 volume with 395 trades. The average volume for the last 60 days is 163,771 and the stock's 52-week low/high is $0.201/$1.27.

RespireRx Pharmaceuticals, Inc. (RSPI)

Marketwired, MarketWatch, InvestorsHub, and Barchart reported on RespireRx Pharmaceuticals, Inc. (RSPI), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

RespireRx Pharmaceuticals, Inc. is a leader in the development of medicines for respiratory disorders. These disorders include sleep apneas and drug-induced respiratory depression. The Company formerly went by the name Cortex Pharmaceuticals, Inc. It changed its corporate name to RespireRx Pharmaceuticals, Inc. in December of 2015. RespireRx Pharmaceuticals is based in Glen Rock, New Jersey.

The Company has filed greater than 400 patents in the U.S. and offshore that claim composition of matter, use, formulation, dosage, and mechanism of action. Use claims include treating sleep apnea and preventing or rescuing drug-induced respiratory depression, and also for improving memory and cognition, treating schizophrenia and other central nervous system indications.

RespireRx’s pharmaceutical candidates in development are derived from two platforms. One platform is the class of compounds namedd cannabinoids. This includes, in particular, Dronabinol.

Dronabinol (D9-THC, D9-tetrahydrocannabinol) is an oral capsule drug product. It is undergoing testing for clinical efficacy in patients with obstructive sleep apnea (OSA). Under a license agreement with the University of Illinois, the Company has rights to patents claiming the use of cannabinoids for the treatment of sleep-related breathing disorders.

Dronabinol (D9-THC) is a generic, orally active cannabinoid. It has been shown to act at CB1 & CB2 receptors on neurons to stabilize respiratory patterns and augment upper airway muscles. Two Phase 2 clinical trials have been completed. Both have demonstrated considerable reductions in sleep apnea produced by dronabinol.

The other platform of medicines undergoing development by RespireRx Pharmaceuticals is a class of proprietary compounds named ampakines. These act to enhance the actions of the excitatory neurotransmitter glutamate at AMPA glutamate receptor sites in the brain. Several ampakines, in oral and injectable form, are undergoing development by the Company for the treatment of a variety of breathing disorders.

At the end of November 2017, RespireRx Pharmaceuticals announced that the results of the PACE (Pharmacotherapy of Apnea by Cannabimimetic Enhancement) clinical trial were published by the principal investigators, Dr. Pyllis Zee and Dr. David Carley at Northwestern University and at the University of Illinois at Chicago, respectively. The PACE paper is published in the journal SLEEP, which is the official publication of the Sleep Research Society. Additionally, it is the foremost peer-reviewed journal in sleep and circadian science. Once per night treatment with Dronabinol provides statistically significant improvement in clinical measures of obstructive sleep apnea.

Last month, RespireRx Pharmaceuticals announced that a paper detailing the neurobiologic safety of the ampakine CX717 was accepted for publication by Toxicological Sciences, the Journal of the American Society of Toxicology. The paper, co-authored by RespireRx scientists in association with expert pathologists from around the nation who contributed to a wide-ranging neuropathology research program, presents clear scientific evidence that vacuoles discovered upon histological evaluation of brain tissue samples from animals treated with high doses of CX717, and which halted RespireRx’s promising CX717 clinical development effort, were actually an artifact of tissue processing rather than a toxic drug effect.

RespireRx Pharmaceuticals, Inc. (RSPI), closed Tuesday's trading session at $1.67, up 19.29%, on 2,863 volume with 18 trades. The average volume for the last 60 days is 2,180 and the stock's 52-week low/high is $0.80/$4.15.


The QualityStocks
Company Corner


Epazz, Inc. (EPAZ)

The QualityStocks Daily Newsletter would like to spotlight Epazz, Inc. (EPAZ). Today, Epazz, Inc. closed trading at $0.0903, off by 20.37%, on 550,803 volume with 87 trades. The stock’s average daily volume over the past 60 days is 541,938, and its 52-week low/high is $0.0045/$0.52.

Epazz, Inc. (OTC: EPAZ) is a leading provider of blockchain cryptocurrency mobile apps and cloud-based business software solutions that specializes in providing customized web applications to the corporate world, higher education institutions and the public sector. The company’s strategic expansion into the investment fintech software space can be seen in the recent acquisition of the android app CryptoFolio, which securely tracks and manages Bitcoin and Altcoin portfolios.

Epazz, Inc. (EPAZ), is a leading provider of blockchain cryptocurrency mobile apps and cloud-based business software solutions that specializes in providing customized web applications to the corporate world, higher education institutions and the public sector. The company's strategic expansion into the investment fintech software space can be seen in the recent acquisition of the android app CryptoFolio, which securely tracks and manages Bitcoin and Altcoin portfolios. Epazz, Inc., which acquired the software rights, source code and user base of CryptoFolio, plans to add additional cryptocurrencies and languages to the app, along with an iOS version to attract more users.

Epazz also offers ZenaPay Bitcoin wallet, which has been downloaded more than 10,000 times since its launch on the Play Store. A subsidiary of Epazz, ZenaPay is a financial technology company that offers a unique, secure and reliable Bitcoin payment app, allowing consumers to acquire Bitcoin at the point-of-sale. The consumer can then use this digital currency to make a purchase with ease. The CryptoFolio business model provides free features to attract users and then allows users to purchase additional features from $1.99 to $5.99 each. CryptoFolio is a great add-on app for ZenaPay, and future versions of CryptoFolio will include an option to download ZenaPay.

"We are starting 2018 with ZenaPay on both major mobile apps' platforms," said Shaun Passley, PhD, CEO and founder of Epazz. "We are in the processing of developing new blockchain technology which will introduce an additional source of revenue streams for our company."

Epazz technology makes it easy to convert legacy systems into cloud business process software, for which the company then charges an annual subscription fee. Epazz has acquired 11 software companies that have converted or are in the process of converting their legacy software products to cloud software using Epazz technology. Epazz then markets the new cloud-based solutions to new and existing customers.

Epazz's unique BoxesOS™ applications can create virtual communities for enhanced communication, provide information and content for decision-making, and create a secure marketplace for any type of commerce. Epazz has also filed a provisional patent for its new blockchain smart legal contract technology that reduces fraud in business transactional contracts. The technology allows for a transactional contract to become a living contract that is tracked and traced; it also verifies that a section of terms within a contract are followed and that all parties of an agreement obey the terms of the contract.

"Blockchain-based technology is the future of the Internet," Passley said. "Epazz will add blockchain technology to all of our products in the coming months using our blockchain cloud platform, BoxesOS. The company has been working with customers to understand the best uses of blockchain, and we are excited about filing the first of many blockchain patents, with many more to come." Disclaimer

Epazz, Inc. Company Blog

Epazz, Inc. News:

Epazz, Inc. (EPAZ) is “One to Watch”

Epazz Acquires CryptoFolio Android App for Tracking Bitcoin and Altcoin Portfolios, Expands into the Investment FinTech Software Space

EVIO Inc. Featured on MoneyTV with Donald Baillargeon, 1/19

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.0337, up 12.33%, on 10,074,249 volume with 362 trades. The stock’s average daily volume over the past 60 days is 54,337,327, and its 52-week low/high is $0.009/$0.16.

Global Payout, Inc. (GOHE) today released the upcoming schedule of its logistics supply chain finance subsidiary, SecurCapital Corp participation in industry leading Fintech & Blockchain Conferences in China, United Kingdom and United States. SecurCapital is introducing a disruptive "one-click solution" offering Fintech services in the underserved trillion-dollar Supply Chain Finance marketplace.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

Global Payout, Inc. announces Logistics Subsidiary - SecurCapital Corp upcoming global schedule of Fintech & Blockchain Conferences

MoneyTrac Technology, Inc. Establishes Joint Venture with Integrated Compliance Solutions, LLC, to Augment Compliance Services in Cannabis Industry

NetworkNewsAudio Announces Audio Press Release (APR) on Next-Generation Solutions Leveraging Blockchain

MGX Minerals Inc. (MGXMF)

The QualityStocks Daily Newsletter would like to spotlight MGX Minerals Inc. (MGXMF). Today, MGX Minerals Inc. closed trading at $1.2594, up 1.56%, on 178,341 volume with 205 trades. The stock’s average daily volume over the past 60 days is 560,161 and its 52-week low/high is $0.543/$2.119.

MGX Minerals Inc. (CSE:XMG) (FKT:1MG) (OTCQB:MGXMF) is pleased to announce that wholly-owned subsidiary ZincNyx Energy Solutions, Inc. (“ZincNyx”) has commenced development of a scaled-up 20 kW system for use in utility-scale battery storage.

MGX Minerals Inc. (CSE: XMG) (FKT: 1MG) (OTCQB: MGXMF) is a diversified Canadian resource company developing large-scale mineral portfolios in specific commodities and jurisdictions in North America. The company controls significant interest in lithium, magnesium and silicon assets that offer streamlined development timelines and low capital expenditures. MGX Minerals and its engineering partner have developed a patent-pending, low-energy design process to extract valuable minerals from the abundant, highly mineralized brine wastewater produced each year by oil and gas companies.

This proprietary, petrolithium process rapidly concentrates lithium and other minerals from brine in less than a day. That's a stunning advancement from the conventional method of extracting minerals from brine through an evaporation process that can take up to 18 months, requires hundreds of acres of land, and averages less than a 50 percent mineral recovery rate. Using this advanced water purification technology, MGX Minerals cleans the wastewater that accompanies petroleum as it's being pulled up to the surface. The company's petrolithium process eliminates the need to inject contaminated wastewater back into the ground, which prevents drinking water contamination and possible earthquakes.

In January 2017, MGX Minerals successfully recovered concentrated lithium from heavy oil evaporator blowdown wastewater using its rapid recovery process, an accomplishment independently confirmed by the Saskatchewan Research Council. In August 2017, the company also successfully processed wastewater and lithium brine from eight North American projects at its one-cubic-meter-per-hour processing plant, proving the technology is economically viable. Research group Global Water Intelligence expects the wastewater treatment industry to grow into a $45 billion market annually by 2025, which suggests there are ample revenue-generating opportunities for MGX Minerals technology.

Lithium, the "white gold" of the new energy economy, is the key to clean energy development as global demand for hybrid and electric vehicles, high-drain portable electronic devices, and large-scale energy storage systems ramps up. Grand View Research, Inc. reports that the global lithium-ion battery market is expected to reach $93.1 billion by 2025. Current market forces show a high demand for lithium and a low supply, which further supports the necessity of MGX Mineral's cleaner, faster method of extracting high-value minerals from brine wastewater.

MGX Minerals is led by a team of industry standout performers who have worked in the mining and technology industries for decades. The leadership team is joined by an array of top-notch technical partners with unmatched experience in the oil and gas sectors, environmental services industry, marketing and product development, along with applied research and commercial development of technologies. Disclaimer

MGX Minerals Inc. Blog

MGX Minerals Inc. News:

MGX Minerals Commences Development of Next Generation Zinc Air Mass Storage System

MGX Minerals Increases Ownership Stake in Cleantech Engineering Partner PurLucid Treatment Solutions to 51%

MGX Minerals Announces 1.79% Li 186ppm Ta Over 6m at Case Lake Lithium, Ontario

Skinvisible, Inc. (SKVI)

The QualityStocks Daily Newsletter would like to spotlight Skinvisible, Inc. (SKVI). Today, Skinvisible, Inc. closed trading at $0.024, even for the day, on 276,429 volume with 14 trades. The stock’s average daily volume over the past 60 days is 527,040 and its 52-week low/high is $0.02/$0.33.

Skinvisible’s (OTCQB: SKVI) innovative DermSafe product incorporates the company’s proprietary Invisicare® drug delivery technology and has proven effective against a variety of infectious germs. An article discussing the topical and transdermal product development company reads: “The main curse this season is the particularly malevolent influenza virus H3N2. It is the most dominant strain not only in the U.S. but in Canada and the UK.

Skinvisible, Inc. (SKVI) through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., is a Research and Development company whose patented Invisicare® technology can be used to revitalize or create new medical or skincare products, allowing a company that licenses Skinvisible's formulations to sell their own patented product and combat generic competitors.

A prescription dermatology product can generate $100 million or more a year, with the potential to lose 50-90% of that revenue when it goes off patent. Preserving that revenue is why the licensing of a product made with Invisicare is a very desirable option for many companies. The Company has developed a pipeline of 40 products using Invisicare, with a primary focus on optimizing the performance and increasing the value of "gold standard" dermatology drugs and licensing them to international and multi-national companies in the pharmaceutical, over-the-counter and cosmeceutical markets.

Invisicare® is a high performance topical and transdermal delivery system which enhances the delivery of drugs and other ingredients to and through the skin. The key to Skinvisible's patented technology and trademarked Invisicare® family of polymer delivery vehicles is its formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. Invisicare® can be a key component of life cycle management, extending the life with a new patent-protected product, dramatically expanding the company's revenue stream.

Independent studies of Invisicare® have shown the following benefits:

  • Active ingredients stay on the skin for up to four hours or more and resist wash off and rub off.
  • Delivery method results in improved efficacy, reduced skin irritation and lower required dosage.
  • Unique formulations are non-drying and provide the ability to control the release of active ingredients.
  • Products form a protective barrier, which means normal skin respiration and perspiration occur and the product wears off as part of the skin's natural exfoliation process.

Terry Howlett, President, founder and CEO of Skinvisible Inc., said the Company has more than 15 years of scientific research and product development experience. All development is conducted using stringent pharmaceutical standards. The Company has licensed a number of its formulations including a prescription hemorrhoid cream in the USA, its anti-aging Kintari® line of products and DermSafe®, its non-alcohol hand sanitizer to a licensee in China. Producing licensed products for the booming cannabis industry is also an important element of the company's business strategy.

Skinvisible's foray into the rapidly expanding market for medicinal and recreational cannabis products is already underway with the development of the company's first hemp-derived CBD (cannabidiol) products. Skinvisible has negotiated an exclusive licensing deal in Canada with Canopy Growth Corporation, one of the world's leading cannabis companies. As part of the company's overall growth strategy, Skinvisible is also negotiating with a Licensed Producer in Las Vegas where Skinvisible scientists will develop THC (tetrahydrocannabinol) products for the legal recreational and medical marijuana market for the USA. Notably, Skinvisible is actively pursuing potential licensees through-out the world where medical cannabis is legal. These licensees will have the exclusive right to manufacture and distribute Skinvisible's cannabis products within their territory.

"We are excited about the results we are already seeing just with our hemp-derived CBD products," Howlett says. "Our science shows that our CBD products release almost four times that of market leaders and our transdermal product had an 81% penetration rate at 6 hours. These results are significant and provide the difference between ordinary cannabis products and ones enhanced by Invisicare."

The Company's business model includes out-licensing its formulations for a development fee, license fee and on-going royalties in addition to selling its Invisicare polymers to its licensees. Disclaimer

Skinvisible, Inc. Blog

Skinvisible, Inc. News:

NetworkNewsBreaks – Skinvisible, Inc.’s (SKVI) DermSafe Offers Long-term Protection Against H3N2 Flu Virus

DermSafe from Skinvisible, Inc. (SKVI) Kills Killer Flu Virus H3N2 For Up to Four Hours

CannabisNewsBreaks – Skinvisible, Inc. (SKVI) to Enter Pain Management Therapeutics Market through Proposed Merger

AV1 Group, Inc. (AVOP)

The QualityStocks Daily Newsletter would like to spotlight AV1 Group, Inc. (AVOP). Today, AV1 Group, Inc. closed trading at $0.033, up 9.63%, on 90,661 volume with 11 trades. The stock’s average daily volume over the past 60 days is 51,323 and its 52-week low/high is $0.017/$0.28.

AV1 Group, Inc. (AVOP), a publicly traded investment and holding company, today announced the engagement of Mr. Jon Fortune.  With over 15 years in the energy industry spanning project planning, policy, and strategic development of renewable energy and storage systems, Mr. Fortune’s insights have successfully shaped markets and businesses globally.

AV1 Group, Inc. (AVOP), is a publicly traded investment and holding company established to identify, secure and monetize emerging growth companies in a number of sectors that include cannabis related technologies, grow houses and cultivation, and e-commerce businesses positioned for exponential growth. After identifying businesses displaying revolutionary concepts able to develop a substantial footprint in high-growth markets, the business model followed calls for incubating and supporting the best opportunities.

The company seeks to discover inspired entrepreneurs with innovative ideas that are poised for significant revenue generation. Management expertise can be seen in the development of embryonic-stage subsidiaries as the company brings a spectrum of backgrounds to the table with a significant resource of knowledge and experience to every venture. AV1 Group explores every opportunity to help each sector exceed its revenue goals while building close, active working relationships as it prepares each respective division to be a robust competitor within the various chosen markets.

AV1 Group companies include:

  • XFIRESmartSystems.com – Intelligent lighting solutions and wireless access for many different applications.
  • VaporHighUSA.com – Over 800 vaping products; bitcoin payments accepted.
  • DentalCannatizer.com – Revolutionary dual jet dental water jet integrates hemp oil infusing.
  • IntelligentLightingCorp.com – Comprehensive, energy-efficient lighting solutions.
  • CannaLighting.com – Wholly owned subsidiary building strategic relationships in the LED sector to provide solutions for grow houses and cultivation centers.
  • MJIQ – First, comprehensive, enterprise-grade integrated software suite being developed for the legal cannabis industry.
  • Hemptory.com – Engaging online destination for all hemp and cannabis related products and services.
  • Lawster.com – Puts consumers and small businesses in contact with legal services and service providers.
  • MJTestLabs.com – Under development website will serve cannabis dispensaries, laboratories and industry affiliates.

AV1 Group's business model delivers an advantage with internally-created projects that are poised for revenue generation and a cross-company revenue platform that enables the company to incubate and foster growth in early-stage subsidiaries under one umbrella. Disclaimer

AV1 Group, Inc. Blog

AV1 Group, Inc. News:

AV1 Group Announces Engagement of Strategic Corporate Advisor to Assist in Propelling LED Division

NetworkNewsBreaks – AV1 Group, Inc.’s (AVOP) Smart Solutions Helping to Guide Modern Urban Development

AV1 Group, Inc. (AVOP) is Providing the Ideas and Solutions to Make Our Cities Smarter

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.067, off by 0.74%, on 12,053,520 volume with 573 trades. The stock’s average daily volume over the past 60 days is 13,467,027, and its 52-week low/high is $0.0132/$0.415.

Less than a decade ago, blockchain sounded like the fodder of science fiction; today, the technology is demonstrating its ability to revolutionize the finance industry. By stepping outside the existing payment structures, blockchain provides a new and secure way to execute financial transactions. The use of the technology is rapidly expanding, and because of the innovative nature of the technology, its wide-ranging possibilities are being explored and developed by a range of companies with unique objectives. Some, such as SinglePoint, Inc. (SING), are looking at how to integrate these technologies to provide a better service for select markets.

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

How Blockchain is Transforming Payments and More

CannabisNewsBreaks – SinglePoint, Inc. (SING) CEO Discusses New National Ad Campaign in Interview on MoneyTV

SinglePoint, Inc. (SING) Remains Bullish Regarding Use of Bitcoin, Blockchain Technologies to Solve Cannabis Industry’s Payment Problems

Petroteq Energy Inc. (TSX.V:PQE) (OTCQX:PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (PQEFF). Today, Petroteq Energy Inc. closed trading at $1.33, up 6.40%, on 146,723 volume with 190 trades. The stock’s average daily volume over the past 60 days is 502,258, and its 52-week low/high is $0.015/$1.8892.

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF), a company focused on the development and implementation of proprietary technologies for the energy industry, remains devoted to delivering increased transparency while providing users with improved productivity and lower costs.

Petroteq Energy Inc. (TSX.V: PQE) (OTCQB: PQEFF), with headquarters in Canada, seeks to create the world's largest pure-play cobalt exploration and development company. The company's current focus is on its Greater Cobalt Project located in Silver Centre, Ontario. The company is also in the midst of a three-way merger with Cobalt One Ltd. and CobalTech Mining Inc. and on completion First Cobalt will control over 10,000 hectares of prospective land and 50 historic mining operations in the Cobalt Camp in Ontario, Canada, as well as a mill and a permitted refinery facility.

The merger agreements with Cobalt One Ltd. and CobalTech Mining Inc., announced earlier this year, will result in a combined land position of more than 10,000 hectares (nearly 25,000 acres) in the Cobalt Camp containing approximately 50 past cobalt/silver producers and working mines. Initial test results from a mineralogical assessment of sample material taken from various historical mines located throughout the Cobalt Camp show both cobalt-rich and silver-rich mineralization styles. Samples taken at the former Bellellen mine, located within the Greater Cobalt Project in Ontario, show high grade cobalt assays, prompting First Cobalt to increase its drilling program at that site.

Petroteq Energy Inc. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world's current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

The company's clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, Petroteq Energy Inc. and its mining interests are primed for success.

Petroteq Energy Inc. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance. Disclaimer

Petroteq Energy Inc. Company Blog

Petroteq Energy Inc. News:

NetworkNewsBreaks – Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF) Devoted to Improving Transparency, Productivity through Blockchain-based Platform

NetworkNewsAudio Announces Audio Press Release (APR) on Blockchain's Core Value in Global Supply Chain Management

Petroteq Energy Announces Update on Private Placements

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF). Today, PreveCeutical Medical Inc. closed trading at $0.3986, off by 11.42%, on 25,315 volume with 13 trades. The stock’s average daily volume over the past 60 days is 5,689, and its 52-week low/high is $0.01/$0.80.

PreveCeutical Medical Inc. (CSE:PREV) (OTCQB:PRVCF) (FSE:18H), announces that, further to its news release dated August 8, 2017, it has entered into a research and option agreement (the “Research Agreement”), with the University of Queensland (“UQ”) and UniQuest Pty Limited (“UniQuest”), UQ’s main commercialisation company. 

PreveCeutical Medical Inc. (PRVCF), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word "PreveCeutical" – a combination of the words "preventive" and "pharmaceutical" – was a precursor to the company's formation and incorporation in October 2015.

The company's first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical's research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical's gene-silencing technology would effectively "turn off" the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical's science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland's (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.'s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company's core. Disclaimer

PreveCeutical Medical Inc. Company Blog

PreveCeutical Medical Inc. News:

PreveCeutical Signs Research and Option Agreement with UniQuest Pty Limited for Development of Non-Addictive Analgesic Peptides

NetworkNewsAudio Announces Audio Press Release (APR) on the Cannabis Industry Driving Medical Therapy R&D

NetworkNewsWire Announces Publication on Advancements in Cannabis Industry Biotech Therapy

ChineseInvestors.com, Inc. (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com, Inc. (CIIX). Today, ChineseInvestors.com, Inc. closed trading at $0.713, up 2.59%, on 117,451 volume with 97 trades. The stock’s average daily volume over the past 60 days is 546,461 and its 52-week low/high is $0.40/$2.44.

The widespread adoption of cryptocurrencies and blockchain technologies is all but inevitable. The technologies demonstrate numerous consumer and commercial advantages, particularly in logistics, international trade, and even food-safety and product anti-counterfeiting drives. As global and online commerce expands, so does the need for streamlined verification of product quality, delivery and payments, a few of the many capabilities offered by blockchain technology. An emerging leader in this space is ChineseInvestors.com (CIIX), which, among other cryptocurrency-related endeavors, recently opened a bitcoin ATM at its U.S. headquarters in California.

Founded in 1999, ChineseInvestors.com, Inc. (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com, Inc. Blog

ChineseInvestors.com, Inc. News

Sino Adoption of Blockchain Technologies, Cryptocurrencies on Horizon

NetworkNewsAudio Announces Audio Press Release (APR) on Crypto and Blockchain Concepts Taking Root with Investors

NetworkNewsWire Announces Publication on Widening Investment Interests in Blockchain and Cryptocurrencies


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(FUSZ) +78.28%


(OSCI) +24.77%


(GKIT) +19.57%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251